Please login to the form below

Not currently logged in
Email:
Password:

Joachim Hasenmaier joins Boehringer’s board in senior shake-up

Company also appoints new board division of biopharmaceuticals and operations to reflect increased focus on biosimilars

Joachim Hasenmaier - BoehringerBoehringer Ingelheim has appointed Dr Joachim Hasenmaier (pictured) to its board of managing directors to head both consumer and animal health in a series of changes at the top for the German pharma company.

Dr Hasenmaier, who assumes his new role from October 1, 2012, has been with Boehringer since 2001, serving initially as divisional head, animal health, before taking over as regional business manager for Northern Europe and Canada in 2011.

“Joachim Hasenmaier's appointment is the outcome of a long term human resource strategy,” said Christian Boehringer, chair of the company's shareholders' committee.

“Recognising the special focus of animal health and the consumer healthcare business on the end-customer, it is meaningful to combine responsibilities in one board division.”

In addition, Professor Wolfram Carius, previously responsible for the board division of human resources and operations, will take charge of the new board division of biopharmaceuticals and operations to reflect Boehringer's increased focus on biosimilars.

Board chair Professor Andreas Barner will take over responsibilities for human resources as well as remaining board member for research & development and medicine.

The finance board division has also now been “distinctly separated” from the rest of the board divisions, with responsibility to remain with Hubertus von Baumbach.

Engelbert Tjeenk-Willink also stays in charge of Boehringer's prescriptions medicine business.

10th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics